Related Experiment Video

Updated: Jan 10, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.6K

Retraction Note: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets

Deepika Kanojia1, Manoj Garg2, Jacqueline Martinez3

  • 1Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore. csidk@nus.edu.sg.

Journal of Hematology & Oncology
|November 28, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

19.0K

Related Experiment Videos

Last Updated: Jan 10, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

19.0K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K

Articles linked to this work by shared authors, journal, and citation graph.

Correction: Shyamsunder et al. THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. Int. J. Mol. Sci. 2022, 23, 1207.

International journal of molecular sciences·2026

Harnessing MDM2-Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

qChIP-MS reveals the local chromatin composition by label-free quantitative proteomics.

Nature communications·2026

XPO1 inhibitor KPT-330 disrupts the core transcriptional regulatory circuitry of dedifferentiated liposarcoma by modulating the translation process.

Oncogene·2026

Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review.

Journal of Zhejiang University. Science. B·2025

The MLL3/GRHL2 complex regulates malignant transformation and anti-tumor immunity in squamous cancer.

The Journal of experimental medicine·2025

Current and future therapies for triple-negative breast cancer.

Journal of hematology & oncology·2026

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.

Journal of hematology & oncology·2026

Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data.

Journal of hematology & oncology·2026

CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.

Journal of hematology & oncology·2026

Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities.

Journal of hematology & oncology·2026

Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications.

Journal of hematology & oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us